| News
Pharmaceutical industry is driving the Swiss economy
22.11.2017
The number of jobs in the pharmaceutical industry is on a steady rise – and other industries are benefiting from the success of the pharmaceutical companies. According to a new study from BAK Economics, the pharmaceutical industry is the most important driver of growth in Switzerland as a centre of industry.

(img: Bürogebäude Bau 1/Roche)
The number of jobs in the pharmaceutical industry has increased by 12,000 positions in the past ten years. In 2016, Swiss pharmaceutical companies offered around 43,000 full-time jobs, with each job in the pharmaceutical industry generating around four times more added value as the overall economic average. These figures come from a new study from the independent economic research institute BAK Economics and the consulting firm Polynomics on behalf of the association Interpharma.
According to the study, other industries are also benefiting from the successful economic activities of the pharmaceutical industry. Calculations show that every franc of added value from the pharmaceutical industry is worth an additional 70 rappen of added value in other industries as a result of supplier orders. This results in a direct added value contribution of 49.6 billion Swiss francs, or just under 8 per cent of the economy’s total gross added value. In addition, each additional job in the pharmaceutical industry creates an additional 3.2 full-time jobs in companies in other industries.
Overall, the pharmaceutical industry is the most important driver of growth in Switzerland as a centre of industry, finds the study. Around one-fifth of Switzerland’s real economic growth came from the Swiss pharmaceutical industry.
The success of the pharmaceutical industry is partly due to the attractive conditions in which it operates in Switzerland. For large pharmaceutical companies, this includes unbureaucratic access to important export markets, the availability of qualified staff, competitive corporate taxation, as well as the fact that the excellence of Switzerland as a centre of research is ensured.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read MoreBSI integrating AI from Parashift in banking software
Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...
Read MoreUptownBasel joins IBM Quantum Network
UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...
Read MoreSouth Korean pharma firms show interest in the Basel Area
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...
Read More